314 results about "Drug release rate" patented technology

Methods and apparatus for improving administration of drugs through the use of heat and other physical means. The present invention relates to the use of heat and other physical means in conjunction with specially designed dermal drug delivery systems, conventional commercial dermal drug delivery systems, or drugs delivered into a sub-skin depot site via injection and other methods to alter, mainly increase, the drug release rate from the dermal drug delivery systems or the depot sites to accommodate certain clinical needs.

Coatings and methods of forming coatings for implantable medical devices, such as stents, are described. The coatings are used for the sustained release of a therapeutic agent or drug.

Disclosed herein are biocompatible durable controlled drug releasing polymeric coatings for medical devices. The drug release rates of the polymers are controlled by adjusting monomer ratios and glass transition temperatures Tgs. The polymers are durable; they do not delaminate from the coated medical device.

A method of making a drug eluting stent comprises forming a porous stent body surface layer by ion implantation, applying a layer of ceramic particles on the porous layer and compressing the layer of ceramic particles. The layer of ceramic particles can be compressed to successively higher densities. Drugs can be loaded into the layer of ceramic materials at a relatively low density before the layer of ceramic materials is compressed to a higher density to achieve a desired low drug release rate.

The present invention is an apparatus and a method for delivery of mitomycin through an eluting biocompatible implantable medical device. A biocompatible drug release matrix comprises a biocompatible drug release matrix and a drug incorporated into the biocompatible drug release matrix. The drug has antibiotic and anti-proliferative properties and is an analogue related to the quinone-containing alkylating agents of a mitomycin family. The drug is initially released from the biocompatible drug release matrix at a faster rate followed by a release at a slower rate. The drug release rate maintains tissue level concentrations of the drug for at least two weeks after implantation of the medical device. The present invention provides a coating for a vascular prosthesis that elutes the drug at a controlled rate to inhibit proliferation of smooth muscle cells causing restenosis.

A preparation method of a drug sustained-release stent includes a preparation stent, a drug sustained-release stent constituted by drug coating on the stent, and the drug coating of the stent is composed of the following steps sequentially: (1) the preparation of a sustained-release drug coating layer; (2) the coating of the sustained-release drug coating layer; (3) drying. The dosages of the drug components on the sustained-release drug stent of the invention are in line with the designed dosages, and the drug can be released according to the stipulated dosages in the stipulated time of the design requirements completely in vitro tests. The invention has good biocompatibility, low cost of spraying process, high yield, controllable thickness of the coating layer, and slow and stable drug release rate.

Coatings and methods of forming coatings for implantable medical devices, such as stents, are described. The coatings are used for the sustained release of a therapeutic agent or drug.

Methods of modifying properties such as degradation rate and drug release rate of polymer stents with radiation are disclosed.

The invention discloses a multi-layer drug sustain-release nano fiber membrane and a preparation method thereof. The inner layer and outer layer of the multi-layer membrane are both composed of a polymer A nano fiber with a good biological compatibility, and the middle layer is a drug-carrying nano fiber which is prepared by blending curcumin (CM) and a polymer B with a good biological compatibility. The preparation method comprises the following steps: dissolving the polymer A into a solvent, subjecting the polymer A to an electrostatic spinning process so as to prepare the inner layer, then subjecting a mixed solution of the polymer B and CM to an electrostatic spinning process, continuously depositing the mixed solution on the inner layer so as to obtain the middle layer, finally subjecting the polymer A to an electrostatic spinning process for a second time, and continuously depositing the polymer A on the middle layer so as to obtain the outer layer. The membrane preparation method is simple, can effectively relieve the burst release phenomenon in the early release stage, and can control the drug release by changing the thickness of the polymer A. Taking polymer A-polylactic acid (PLA), and polymer B-cellulose acetate (CA) as an example, the in vitro drug release test results have shown that the drug release rate of the multi-layer drug-carrying membrane is both less than that of a single layer drug loaded membrane no matter after 1 hour or after 240 hours.

A coated implantable medical device and a method of coating an implantable medical device is disclosed, the method includes applying a composition onto the device and drying the composition at elevated temperature in an environment having increased relative humidity. A pre-screening method for a manufacturing lot of coated stents to determine the number of drug coating layers for a desired drug release rate is disclosed. The method including coating and testing small groups of stents, and applying the results of the tests to determine the number of drug coating layers to apply to the manufacturing lot of stents.

A method of enhancing the drug release rate from a composite material. The composite material includes a synthetic, bioabsorbable polymer matrix and a drug particle phase dispersed therein. The release rate of the drug from the polymer matrix is enhanced by orienting the composite material. The drug release rate of the oriented composite material is greater than the drug release rate from an otherwise comparable non-oriented composite material.

Disclosed is a polymer conjugate of folic acid or a folic acid derivative, wherein an amide bond is not used. The compound has chemical stability and adequate drug release rate in the living organism. Specifically disclosed is a polymer conjugate of folic acid or a folic acid derivative, wherein a substituent represented by formula (I) is bonded to a carboxy group of a block copolymer which is composed of a polyethylene glycol and a polymer having a carboxy group in a side chain, or a pharmacologically acceptable salt thereof.[In the formula, A represents a monocyclic or fused aromatic group; G represents an optionally substituted (C1-C6) alkylene group; Y represents a hydrogen atom or a substituent; and E represents a residue of folic acid or a folic acid derivative.]

The invention relates to a method for preparing a shell-sheddable polymer micelle drug carrier. The drug carrier is a disulfide bond bridging amphiphilic copolymer, and the disulfide bond can be rapidly cracked under reduction environment in cells to realize the intelligent drug release function through the shell shedding, so the amphiphilic copolymer can rapidly self-assemble into micelle nanoparticles and loading drugs in water. Compared with drug carriers prepared with the prior art, the shell-sheddable polymer micelle drug carrier allows the drug release rate under high concentration glutathione environment to be 3-5 times faster than the drug release rate under glutathione-free environment, can be used to control the release of drugs in tumor cells, and has obvious inhibition on the tumor cells, and the drug carrying micelle particles can stably clad anticancer drugs, so a novel high efficiency drug carrier system is provided for the tumor treatment.

The invention discloses halloysite nano composite gel microspheres and a preparation method thereof. The microspheres comprise the following components in percentage by mass: 50-90% of halloysite and 10-50% of a chitosan derivative. The preparation method comprises the following steps: firstly, preparing the halloysite and the chitosan derivative into a suspension and a gel solution respectively; then adding the halloysite suspension into the chitosan derivative gel solution; and finally, after 2-4 hours of reaction at room temperature, preparing the nano composite drug-loaded gel microspheres through an ion-gel method. According to the halloysite nano composite gel microspheres and the preparation method thereof disclosed by the invention, the swelling rate and drug release rate of the microspheres can be reduced, and the halloysite nano composite gel microspheres have pH sensitivity and can be used as intestinal drug slow-release carriers.

A paliperidone double-layered osmotic pump controlled release tablet and the preparation method thereof are disclosed. The double-layered osmotic pump controlled release tablet comprises a rigid membrane, a push layer, a drug layer, an isolation layer and an aesthetic coating, wherein the rigid membrane contains a semi-permeable polymer, a porogen and / or a plasticizer and has one or more drug release orifices on one end, the push layer comprises an expanding material, an osmotic agent, a binder, a colorant and a lubricant, the drug layer contains a pharmaceutically active ingredient, a hydrophilic polymer, an osmotic agent, a colorant, a lubricant and an antistatic agent, the isolation layer is located between the inner surface of the rigid membrane and the push layer, and contains a hydrophilic polymer. The paliperidone double-layered osmotic pump controlled release tablet shows an increasing drug release rate at early stage and keeps a constant drug release rate at later stage.

The invention provides a method for preparing a tiny mesoporous silica drug sustained-release material and a tiny mesoporous hollow tubular silicon dioxide material obtained through the method. The drug loading capacity, calculated through a TG method, of the tiny mesoporous hollow tubular silicon dioxide material for aspirin model drugs is 15%, the sustained-release stage is the time of six hours of the initial stage of an experiment, and the drug releasing rate is high; after six hours, the stage of release balancing is achieved, and the amount of balanced release is 73.6%.

The invention provides a preparation method and application of a Fe3O4@SiO2 yolk-eggshell-structured hollow composite microsphere. The preparation method comprises the following steps: preparing Fe2O3 nanoparticles by using a solvothermal method; under the condition that no surfactant is added and TEOS is used as a silicon source, preparing a Fe3O4@SiO2 composite microsphere with controllable morphology under mild conditions by using a combination of a template method and a hydrothermal method; corroding the Fe3O4@SiO2 composite microsphere with hydrochloric acid with a certain concentration so as to obtain a Fe3O4@SiO2 yolk-eggshell-structured hollow composite microsphere; and carrying out reduction so as to prepare the Fe3O4@SiO2 yolk-eggshell-structured hollow composite microsphere with superparamagnetism. The prepared Fe3O4@SiO2 yolk-eggshell-structured hollow composite microsphere has a specific surface area of 173 m<2> / g and drug loading capacity of 139 mg / g; and with doxorubicin hydrochloride as a drug model, the Fe3O4@SiO2 yolk-eggshell-structured hollow composite microsphere has a drug release rate of as high as 68.4% within 72 h in a PBS buffer solution with a pH value of 7.4, so the composite microsphere presents good slow drug release performance.

A pharmaceutical composition for external use which is an organogel containing a fatty acid ester and a glycerolglycerin fatty acid ester, in particular, a novel transdermally absorbable pharmaceutical composition for external use which has a drug such as non-narcotic analgesics as an active ingredient made in organogel form containing a drug such as non-narcotic analgesics as an active ingredient, a fatty acid ester and a glycerolglycerin fatty acid ester, and a method for producing the composition. The pharmaceutical composition significantly improves skin permeability of drugs such as non-narcotic analgesics and allows a sufficient amount of drug to permeate the skin sustainably. Moreover, since the pharmaceutical composition is in organogel form, it can be easily applied to a preparation in practice. In addition, the pharmaceutical composition can provide efficient use and the like of drugs due to a high drug release rate and therefore is highly useful.

The invention relates to a novel alkylation cage silsesquioxane nanometer hybrid prepared in an alkaline solution, wherein a diameter of hybrid molecules is 1-2 nm, a center of the molecule has a cubic cage type structure, eight vertexes are connected with a product prepared through carrying out ring opening addition on propylamino and 2-ethylhexyl glycidyl ether, and the hybrid has strong hydrophobicity. According to the present invention, the hybrid is dispersed in a 1.5 w% sodium alginate aqueous solution through an emulsification and high speed stirring method, and the obtained solution is added to a 3% calcium chloride aqueous solution in a dropwise manner to prepare a nanometer hybrid modified sodium alginate hydrogel, wherein the obtained modified hydrogel has characteristics of enhanced mechanical strength and enhanced stability compared to the pure sodium alginate hydrogel, and hydrophobic drug embedding rate is increased and drug release rate is slowed when the obtained modified hydrogel is used as a drug carrier.

The invention discloses a tetrodotoxin quick-release pellet preparation and its preparation method and use and relates to the field of a medicinal preparation technology and use. The tetrodotoxin quick-release pellet preparation is suitable for oral administration and utilizes a blank pellet core as a carrier and a tetrodotoxin aqueous solution containing a cosolvent and a binder as a drug feeding solution. A weight ratio of the tetrodotoxin to the pellet core is 0.0025%-0.3% and an oral dosage of the tetrodotoxin is less than or equal to 300 micrograms. The tetrodotoxin quick-release pellet preparation has the advantages of high superimpose rate, good content uniformity, fast drug release rate and fast pain easing. The tetrodotoxin quick-release pellet preparation has the characteristics of good clinical use compliance and high safety. The blank pellet core fluidized bed-based drug superimpose method is suitable for preparation of a very low specification tetrodotoxin oral preparation.

The invention discloses a huperzine A single-layer osmotic pump controlled-release tablet. The controlled-release tablet comprises a tablet core containing huperzine A and pharmaceutic adjuvants in effective dosage, and a semipermeable coating membrane coating the tablet core, wherein the coating membrane is provided with a drug release hole. The controlled-release tablet is characterized in that: the tablet core contains the following components in percentage by weight: 0.01 to 1.0 percent of huperzine A, 1.0 to 10 percent of retarder and 1.0 to 40 percent of permeation enhancer; and the weight ratio of polyethylene glycol 6,000 contained in the coating liquid to cellulose acetate is (0.05-0.25):1, and the weight gain of the coating membrane against the weight of the tablet core is between 5 and 25 percent. The controlled-release tablet has the advantages that the drug release rate is stable, the blood consentration of patients is relatively constant after the patients take the controlled-release tablet, and the drug taking frequency of the patients is reduced, so that the controlled-release tablet is a novel drug formulation which is safer, more effective, stable, controllable and convenient for application in clinically treating senile dementia.

The invention relates to a drug gradient zero-grade implantation controlled release drug delivery device and the preparation method thereof; the drug delivery device takes the controlled release polymer as a frame, the top surface and the bottom surface are formed by bonding of the insoluble polymer, that is, the release resistant materials, and the middle drug is radially distributed according to the gradient. The axial two sides of the drug deliver system are sealed by the polymer, and then the drug is released radially and two-dimensionally; the radial drug concentration difference is obtained by the change of the times of printing and spraying the drug-carrying adhesives, the peripheral drug release area is big, the spraying times are less, and the drug concentration is low; the drug release area of the central area is small, the spraying times are more, and the drug concentration is high. The drug concentration takes the gradient distribution and the drug release rate is constant. The technique has simple preparation, high degree of automation and good reproducibility.

A coating device for coating a medical device with a drug-eluting material uses an in-process drying station between coats to improve a drug release profile. The drying station includes a dryer having a telescoping plenum which provides a drying chamber for the stent or scaffold to reside while a heated gas is passed over the stent / scaffold. The drying chamber improves efficiency in drying, predictability or drug release rate, uniformity of coating material properties lengthwise over the stent / scaffold and provides a platform that can effectively support stents that are over 40 mm in length.

A method for preparing hydro / organo gelators from disaccharide sugars by biocatalysis and their use in enzyme-triggered drug delivery. Controlled delivery of an anti-inflammatory, chemopreventive drug is achieved by an enzyme-triggered drug release mechanism via degradation of encapsulated hydrogels. The hydro- and organo-gelators are synthesized in high yields from renewable resources by using a regioselective enzyme catalysis and a known chemopreventive and anti-inflammatory drug, curcumin, is encapsulated in the gel matrix and released by enzyme triggered delivery. The release of the drug occurs at the physiological temperature and control of the drug release rate is achieved by manipulating the enzyme concentration and temperature. The by-products formed after the gel degradation clearly demonstrated the site specificity of degradation of the gelator by enzyme catalysis. The present invention has applications in developing cost effective, controlled drug delivery vehicles from renewable resources, with a potential impact on pharmaceutical research and molecular design and delivery strategies.

The invention discloses a doxorubicin hydrochloride light-controlled sustained-release liquid crystal gel preparation and a preparation method thereof. The light-controlled sustained-release liquid crystal gel preparation is prepared from 15-40 wt% of phospholipid, 60-70 wt% of glyceride, 1-20 wt% of a cosolvent, 0.01-2 wt% of doxorubicin hydrochloride and 0.001-0.2 wt% of a photosensitizer. The doxorubicin hydrochloride light-controlled sustained-release liquid crystal gel preparation has the advantages of low viscosity, good fluidity, easiness in injection, rapidness in formation of the liquid crystal gel after being injected into or around a tumor or being placed in a post-operative tumor cavity, and realization of in-situ slow release of doxorubicin hydrochloride; and lights cause phase change of the liquid crystal gel and increase the drug release rate, and the preparation prolongs the drug action time, reduces the administration frequency, reduces the toxic and side effects of the drug, releases the drug as needed by adjusting the release of the drug through adjusting the illumination frequency or time according to the tumor pathological conditions of a patient, and greatly improves the bioavailability of the drug.

A method of injecting a mixture into an eye includes: providing the mixture in a dispensing chamber with an air gap located between the mixture and an interior surface of a dispensing chamber housing, when the mixture and dispensing chamber housing are near room temperature; bringing the dispensing chamber housing and mixture to a temperature range, other than near room temperature, at which the mixture expands and is in a more liquid state; maintaining air in a needle after the mixture expands and prior to an injection; selecting a drug release rate; and injecting the mixture so as to form a shape with a surface area that results in the selected drug release rate.

Disclosed herein are biocompatible durable controlled drug releasing polymeric coatings for medical devices. The drug release rates of the polymers are controlled by adjusting monomer ratios and glass transition temperatures Tgs. The polymers are durable; they do not delaminate from the coated medical device.